Literature DB >> 25837734

Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals.

Natalie R Fitzgerald1, William M Flanagan, William K Evans, Anthony B Miller.   

Abstract

OBJECTIVES: The study aimed to incorporate an estimate of risk for asbestos exposure in the Canadian Cancer Risk Management Lung Cancer (CRMM-LC) microsimulation model.
METHODS: In CRMM-LC, a 3-year probability of developing lung cancer can be derived from different risk profiles. An asbestos-exposed cohort was simulated and different scenarios of low-dose computerized tomography (LDCT) screening were simulated.
RESULTS: As annual LDCT screening among non-asbestos-exposed individuals is less cost-effective than biennial screening, all the scenarios modeled for an asbestos-exposed cohort were biennial. For individuals with a two-fold risk of asbestos-induced lung cancer to be eligible for biennial LDCT screening, a smoking history of ≥15 pack-years would be necessary. For non-smokers with asbestos exposure resulting in a relative risk (RR) for lung cancer, it is not cost-effective to screen those with a RR of 5, but it is cost-effective to screen those with a RR of 10 (the heavily exposed).
CONCLUSION: Asbestos-exposed individuals with an estimated two-fold or more risk of lung cancer from asbestos-exposure are eligible for LDCT screening at all ages from 55-74 years if they have a cigarette smoking history of ≥15 pack-years. Asbestos-exposed individuals who are lifelong non-smokers are eligible for LDCT screening at all ages from 55-74 years if they have accumulated a degree of asbestos exposure resulting in an estimated risk of lung cancer of ≥10.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25837734     DOI: 10.5271/sjweh.3496

Source DB:  PubMed          Journal:  Scand J Work Environ Health        ISSN: 0355-3140            Impact factor:   5.024


  6 in total

1.  The relationship between smoking and knee osteoarthritis in the Osteoarthritis Initiative.

Authors:  C E Dubé; S-H Liu; J B Driban; T E McAlindon; C B Eaton; K L Lapane
Journal:  Osteoarthritis Cartilage       Date:  2015-10-17       Impact factor: 6.576

2.  Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Authors:  C Popadiuk; C L Gauvreau; M Bhavsar; C Nadeau; K Asakawa; W M Flanagan; M C Wolfson; A J Coldman; S Memon; N Fitzgerald; J Lacombe; A B Miller
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

3.  Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations.

Authors:  Fleur Delva; Jacques Margery; François Laurent; Karine Petitprez; Jean-Claude Pairon
Journal:  BMC Public Health       Date:  2017-02-14       Impact factor: 3.295

4.  Global coverage and consistency of guideline recommendations for cancer cachexia on the Web in 2011 and 2018.

Authors:  Davide Mauri; Georgia Zafeiri; Melina Yerolatsite; Lampriani Tsali; Georgios Zarkavelis; Anna Tsiara; Nikolaos P Polyzos; Antonis Valachis; Konastantina Kalopita; Eleftherios Kampletsas; Alexandra Papadaki; Evangelia Peponi; Fani Kapoulitsa; Panagiotis Filis; Georgios Pentheroudakis
Journal:  Contemp Oncol (Pozn)       Date:  2019-06-13

5.  Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects.

Authors:  Sébastien Gendarme; Jean-Claude Pairon; Pascal Andujar; François Laurent; Patrick Brochard; Fleur Delva; Bénédicte Clin; Antoine Gislard; Christophe Paris; Isabelle Thaon; Helene Goussault; Florence Canoui-Poitrine; Christos Chouaïd
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

6.  The OncoSim-Breast Cancer Microsimulation Model.

Authors:  Jean H E Yong; Claude Nadeau; William M Flanagan; Andrew J Coldman; Keiko Asakawa; Rochelle Garner; Natalie Fitzgerald; Martin J Yaffe; Anthony B Miller
Journal:  Curr Oncol       Date:  2022-03-03       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.